Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone
Abstract Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral formulations. It has recently been approved by the Food and Drug Administration for the management of acute bacterial skin and skin structure infections. When compared to combination therapy of vancomycin...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2019-03, Vol.68 (6), p.1058-1062 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1062 |
|---|---|
| container_issue | 6 |
| container_start_page | 1058 |
| container_title | Clinical infectious diseases |
| container_volume | 68 |
| creator | Saravolatz, Louis D Stein, Gary E |
| description | Abstract
Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral formulations. It has recently been approved by the Food and Drug Administration for the management of acute bacterial skin and skin structure infections. When compared to combination therapy of vancomycin and aztreonam, delafloxacin was not inferior and had a favorable adverse event profile. Furthermore, its anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and favorable clinical response in MRSA infections distinguishes it from other fluoroquinolones. This review focuses on the mode of action, antimicrobial activity, pharmacokinetics and pharmacodynamics, clinical indications, and safety profile of this drug. Considerations for formulary addition and its place in therapy are also discussed.
Delafloxacin is a new anti-methicillin-resistant Staphylococcus aureus fluoroquinolone with oral and parenteral formulations approved for acute bacterial skin and skin structure infections. Delafloxacin has a favorable adverse event profile, but its clinical utility will require further study. |
| doi_str_mv | 10.1093/cid/ciy600 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_cid_ciy600</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciy600</oup_id><sourcerecordid>10.1093/cid/ciy600</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-63c139c15d7dfbb0e0c562cc1882a150bef71dcea53e84fe57c45abfbe76a74e3</originalsourceid><addsrcrecordid>eNp9kLFOwzAURS0EolBY-ACUhQUp8FzHccJWFQpIFQyUOXJeXlQjNw52IujfExRgZLi6dzi6w2HsjMMVh1xco6mG7FKAPXbEpVBxKnO-P2yQWZxkIpuw4xDeADjPQB6yiQAY6Hx2xNa3ZHVt3adG09xE8-iJPqJ505l4S93GoLHWNLGnYEKnmy566XS72VmHDrEPke49DbW0vfPuvTeNs66hE3ZQaxvo9Ken7HV5t148xKvn-8fFfBWj4KqLU4Fc5Mhlpaq6LIEAZTpD5Fk201xCSbXiFZKWgrKkJqkwkbqsS1KpVgmJKbscf9G7EDzVRevNVvtdwaH4VlMMaopRzQCfj3Dbl1uq_tBfFwNwMQKub_87-gKFyW8D</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Saravolatz, Louis D ; Stein, Gary E</creator><creatorcontrib>Saravolatz, Louis D ; Stein, Gary E</creatorcontrib><description>Abstract
Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral formulations. It has recently been approved by the Food and Drug Administration for the management of acute bacterial skin and skin structure infections. When compared to combination therapy of vancomycin and aztreonam, delafloxacin was not inferior and had a favorable adverse event profile. Furthermore, its anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and favorable clinical response in MRSA infections distinguishes it from other fluoroquinolones. This review focuses on the mode of action, antimicrobial activity, pharmacokinetics and pharmacodynamics, clinical indications, and safety profile of this drug. Considerations for formulary addition and its place in therapy are also discussed.
Delafloxacin is a new anti-methicillin-resistant Staphylococcus aureus fluoroquinolone with oral and parenteral formulations approved for acute bacterial skin and skin structure infections. Delafloxacin has a favorable adverse event profile, but its clinical utility will require further study.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciy600</identifier><identifier>PMID: 30060092</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Drug Resistance, Bacterial ; Fluoroquinolones - chemistry ; Fluoroquinolones - pharmacology ; Fluoroquinolones - therapeutic use ; Humans ; Methicillin-Resistant Staphylococcus aureus - drug effects ; Microbial Sensitivity Tests ; Staphylococcal Infections - drug therapy ; Staphylococcal Infections - microbiology ; Structure-Activity Relationship ; Treatment Outcome</subject><ispartof>Clinical infectious diseases, 2019-03, Vol.68 (6), p.1058-1062</ispartof><rights>The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2018</rights><rights>The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c317t-63c139c15d7dfbb0e0c562cc1882a150bef71dcea53e84fe57c45abfbe76a74e3</citedby><cites>FETCH-LOGICAL-c317t-63c139c15d7dfbb0e0c562cc1882a150bef71dcea53e84fe57c45abfbe76a74e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30060092$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saravolatz, Louis D</creatorcontrib><creatorcontrib>Stein, Gary E</creatorcontrib><title>Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract
Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral formulations. It has recently been approved by the Food and Drug Administration for the management of acute bacterial skin and skin structure infections. When compared to combination therapy of vancomycin and aztreonam, delafloxacin was not inferior and had a favorable adverse event profile. Furthermore, its anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and favorable clinical response in MRSA infections distinguishes it from other fluoroquinolones. This review focuses on the mode of action, antimicrobial activity, pharmacokinetics and pharmacodynamics, clinical indications, and safety profile of this drug. Considerations for formulary addition and its place in therapy are also discussed.
Delafloxacin is a new anti-methicillin-resistant Staphylococcus aureus fluoroquinolone with oral and parenteral formulations approved for acute bacterial skin and skin structure infections. Delafloxacin has a favorable adverse event profile, but its clinical utility will require further study.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Drug Resistance, Bacterial</subject><subject>Fluoroquinolones - chemistry</subject><subject>Fluoroquinolones - pharmacology</subject><subject>Fluoroquinolones - therapeutic use</subject><subject>Humans</subject><subject>Methicillin-Resistant Staphylococcus aureus - drug effects</subject><subject>Microbial Sensitivity Tests</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcal Infections - microbiology</subject><subject>Structure-Activity Relationship</subject><subject>Treatment Outcome</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kLFOwzAURS0EolBY-ACUhQUp8FzHccJWFQpIFQyUOXJeXlQjNw52IujfExRgZLi6dzi6w2HsjMMVh1xco6mG7FKAPXbEpVBxKnO-P2yQWZxkIpuw4xDeADjPQB6yiQAY6Hx2xNa3ZHVt3adG09xE8-iJPqJ505l4S93GoLHWNLGnYEKnmy566XS72VmHDrEPke49DbW0vfPuvTeNs66hE3ZQaxvo9Ken7HV5t148xKvn-8fFfBWj4KqLU4Fc5Mhlpaq6LIEAZTpD5Fk201xCSbXiFZKWgrKkJqkwkbqsS1KpVgmJKbscf9G7EDzVRevNVvtdwaH4VlMMaopRzQCfj3Dbl1uq_tBfFwNwMQKub_87-gKFyW8D</recordid><startdate>20190305</startdate><enddate>20190305</enddate><creator>Saravolatz, Louis D</creator><creator>Stein, Gary E</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20190305</creationdate><title>Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone</title><author>Saravolatz, Louis D ; Stein, Gary E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-63c139c15d7dfbb0e0c562cc1882a150bef71dcea53e84fe57c45abfbe76a74e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Drug Resistance, Bacterial</topic><topic>Fluoroquinolones - chemistry</topic><topic>Fluoroquinolones - pharmacology</topic><topic>Fluoroquinolones - therapeutic use</topic><topic>Humans</topic><topic>Methicillin-Resistant Staphylococcus aureus - drug effects</topic><topic>Microbial Sensitivity Tests</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcal Infections - microbiology</topic><topic>Structure-Activity Relationship</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saravolatz, Louis D</creatorcontrib><creatorcontrib>Stein, Gary E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saravolatz, Louis D</au><au>Stein, Gary E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2019-03-05</date><risdate>2019</risdate><volume>68</volume><issue>6</issue><spage>1058</spage><epage>1062</epage><pages>1058-1062</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Abstract
Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral formulations. It has recently been approved by the Food and Drug Administration for the management of acute bacterial skin and skin structure infections. When compared to combination therapy of vancomycin and aztreonam, delafloxacin was not inferior and had a favorable adverse event profile. Furthermore, its anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and favorable clinical response in MRSA infections distinguishes it from other fluoroquinolones. This review focuses on the mode of action, antimicrobial activity, pharmacokinetics and pharmacodynamics, clinical indications, and safety profile of this drug. Considerations for formulary addition and its place in therapy are also discussed.
Delafloxacin is a new anti-methicillin-resistant Staphylococcus aureus fluoroquinolone with oral and parenteral formulations approved for acute bacterial skin and skin structure infections. Delafloxacin has a favorable adverse event profile, but its clinical utility will require further study.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>30060092</pmid><doi>10.1093/cid/ciy600</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2019-03, Vol.68 (6), p.1058-1062 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_cid_ciy600 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Drug Resistance, Bacterial Fluoroquinolones - chemistry Fluoroquinolones - pharmacology Fluoroquinolones - therapeutic use Humans Methicillin-Resistant Staphylococcus aureus - drug effects Microbial Sensitivity Tests Staphylococcal Infections - drug therapy Staphylococcal Infections - microbiology Structure-Activity Relationship Treatment Outcome |
| title | Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A52%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Delafloxacin:%20A%20New%20Anti-methicillin-resistant%20Staphylococcus%20aureus%20Fluoroquinolone&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Saravolatz,%20Louis%20D&rft.date=2019-03-05&rft.volume=68&rft.issue=6&rft.spage=1058&rft.epage=1062&rft.pages=1058-1062&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciy600&rft_dat=%3Coup_cross%3E10.1093/cid/ciy600%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30060092&rft_oup_id=10.1093/cid/ciy600&rfr_iscdi=true |